Li Tianhao, Wang Henghong, Wang Caiying, Hao Pingsheng
Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
Clin Cosmet Investig Dermatol. 2022 Nov 23;15:2519-2521. doi: 10.2147/CCID.S392280. eCollection 2022.
Conventional treatment suffers from a dilemma of poor efficacy. The clinical use of Janus kinase (JAK) inhibitors in the treatment of steroid-induced rosacea has rarely been explored.
We present a case of steroid-induced rosacea successfully treated with JAK inhibitor tofacitinib, with no adverse effects.
This case report of successful treatment shows a good clinical efficacy of JAK inhibitors tofacitinib in the treatment of SIR.
JAK inhibitor tofacitinib may be a promising agent for the treatment with steroid-induced rosacea, especially for patients who have failed to conventional therapy.
传统治疗存在疗效不佳的困境。Janus激酶（JAK）抑制剂在治疗类固醇诱导的酒渣鼻方面的临床应用鲜有探索。
我们报告一例类固醇诱导的酒渣鼻患者成功使用JAK抑制剂托法替布治疗，且无不良反应。
这例成功治疗的病例报告显示JAK抑制剂托法替布在治疗类固醇诱导的酒渣鼻方面具有良好的临床疗效。
JAK抑制剂托法替布可能是治疗类固醇诱导的酒渣鼻的一种有前景的药物，尤其是对于传统治疗失败的患者。
